Cover Image
市場調查報告書

H5N1感染疾病(禽流感):開發平台分析

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 245964
出版日期 內容資訊 英文 208 Pages
訂單完成後即時交付
價格
Back to Top
H5N1感染疾病(禽流感):開發平台分析 H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016
出版日期: 2016年05月25日 內容資訊: 英文 208 Pages
簡介

所謂H5N1感染疾病是傳染性極強的流感病毒的一種,亦稱之為禽流感,會引起嚴重的呼吸系統疾病。由禽鳥傳染給人類。常見的症狀有發熱、咳嗽、急性呼吸緊迫、呼吸急促/呼吸困難、腹痛、腹瀉等。致病危險因子有照顧家禽的工作,接觸感染的禽鳥,攝取生或加熱不完全的雞肉。

本報告提供H5N1感染疾病(禽流感)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

H5N1感染疾病(禽流感)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

開發治療藥的企業

  • Akshaya Bio Inc.
  • Altimmune, Inc.
  • Antigen Express, Inc.
  • Aphios Corporation
  • BioDiem Ltd
  • BiondVax Pharmaceuticals Ltd.
  • CEL-SCI Corporation
  • Cocrystal Pharma, Inc.
  • CSL Limited
  • 第一三共
  • Emergent BioSolutions Inc.
  • Gemmus Pharma Inc.
  • GlaxoSmithKline Plc
  • Hemispherx Biopharma, Inc.
  • iBio, Inc.
  • Immunovaccine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kineta, Inc.
  • Medicago Inc.
  • MedImmune, LLC
  • Microbiotix, Inc.
  • NanoBio Corporation
  • Nanotherapeutics, Inc
  • NanoViricides, Inc.
  • NewLink Genetics Corporation
  • OPKO Health, Inc.
  • PaxVax, Inc.
  • PeptiDream Inc.
  • Protein Sciences Corporation
  • 鹽野義製藥
  • Sirnaomics, Inc.
  • 武田藥品工業
  • TechnoVax, Inc.
  • TGV-Laboratories
  • Theraclone Sciences, Inc.
  • Vaxine Pty Ltd .
  • VaxInnate Corporation

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

開發中產品的最新趨勢

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8005IDB

Summary

Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016', provides an overview of the H5N1 Infection (Avian Influenza) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H5N1 Infection (Avian Influenza), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H5N1 Infection (Avian Influenza) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza)
  • The report reviews pipeline therapeutics for H5N1 Infection (Avian Influenza) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved H5N1 Infection (Avian Influenza) therapeutics and enlists all their major and minor projects
  • The report assesses H5N1 Infection (Avian Influenza) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for H5N1 Infection (Avian Influenza)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • H5N1 Infection (Avian Influenza) Overview
  • Therapeutics Development
  • H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies
  • H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes
  • H5N1 Infection (Avian Influenza) - Pipeline Products Glance
  • H5N1 Infection (Avian Influenza) - Products under Development by Companies
  • H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes
  • H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development
  • H5N1 Infection (Avian Influenza) - Therapeutics Assessment
  • Drug Profiles
  • H5N1 Infection (Avian Influenza) - Recent Pipeline Updates
  • H5N1 Infection (Avian Influenza) - Dormant Projects
  • H5N1 Infection (Avian Influenza) - Discontinued Products
  • H5N1 Infection (Avian Influenza) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2016
  • Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Altimmune, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Aphios Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by BiondVax Pharmaceuticals Ltd., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by CSL Limited, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by MedImmune, LLC, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Microbiotix, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by NewLink Genetics Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by PeptiDream Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Shionogi & Co., Ltd., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by TGV-Laboratories, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Theraclone Sciences, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Vaxine Pty Ltd, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects, H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..1), H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..2), H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..4), H1 2016
  • H5N1 Infection (Avian Influenza) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2016
  • Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top